Clinical trial
L-carnosine for Schizophrenia
NCT00177177 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00177177 |
|---|---|
| Title | L-carnosine for Schizophrenia |
| Official title | L-Carnosine, an Antioxidant and AGE Inhibitor (Advanced Glycation End Products) for Cognitive Enhancement Among Persons With Schizophrenia: A Randomized, Add-on Double-Blind, Placebo Controlled, Clinical Trial |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Stanley Medical Research Institute |
| Status | Completed |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | L-carnosine (dietary supplement) |
| Enrollment | 84 |
| Start date | Mar 1, 2004 |
| Primary completion | Nov 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: